ATE409065T1 - Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten - Google Patents
Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheitenInfo
- Publication number
- ATE409065T1 ATE409065T1 AT03790505T AT03790505T ATE409065T1 AT E409065 T1 ATE409065 T1 AT E409065T1 AT 03790505 T AT03790505 T AT 03790505T AT 03790505 T AT03790505 T AT 03790505T AT E409065 T1 ATE409065 T1 AT E409065T1
- Authority
- AT
- Austria
- Prior art keywords
- hydroxysteroid dehydrogenase
- inhibitors
- treatment
- compounds
- androgen
- Prior art date
Links
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 title abstract 3
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43410102P | 2002-12-17 | 2002-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE409065T1 true ATE409065T1 (de) | 2008-10-15 |
Family
ID=32713010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03790505T ATE409065T1 (de) | 2002-12-17 | 2003-12-15 | Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7053091B2 (de) |
| EP (1) | EP1572299B1 (de) |
| JP (1) | JP4585320B2 (de) |
| CN (1) | CN1744930A (de) |
| AT (1) | ATE409065T1 (de) |
| AU (1) | AU2003293555A1 (de) |
| CA (1) | CA2509758A1 (de) |
| DE (1) | DE60323765D1 (de) |
| ES (1) | ES2312845T3 (de) |
| MX (1) | MXPA05006485A (de) |
| WO (1) | WO2004060488A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003293555A1 (en) * | 2002-12-17 | 2004-07-29 | Schering Corporation | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| ES2431524T3 (es) * | 2004-04-13 | 2013-11-26 | Incyte Corporation | Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas |
| US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| JP4091095B2 (ja) * | 2004-08-06 | 2008-05-28 | シャープ株式会社 | 送信機、受信機、通信システム、通信方法、通信プログラム |
| ES2931949T3 (es) | 2005-03-29 | 2023-01-05 | Univ Pennsylvania | Minoxidilo para generar nuevos folículos pilosos y tratar la calvicie |
| GB0513702D0 (en) * | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| US20070197590A1 (en) * | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| AU2010234087B2 (en) * | 2009-04-02 | 2016-05-12 | Merck Patent Gmbh | Piperidine and piperazine derivatives as autotaxin inhibitors |
| JP2014500275A (ja) | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
| AU2014300894A1 (en) | 2013-06-25 | 2016-01-28 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
| TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| DE102014005129A1 (de) | 2014-04-08 | 2014-11-06 | Daimler Ag | Verfahren und Fahrerassistenzvorrichtung zur Unterstützung eines Fahrers beim Führen eines Fahrzeugs |
| US10413557B2 (en) | 2014-12-23 | 2019-09-17 | Forendo Pharma Ltd. | Prodrugs of 17.BETA.-HSD1-inhibitors |
| WO2016102775A1 (en) | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | PRODRUGS OF 17β-HSD1 -INHIBITORS |
| CN105461705B (zh) * | 2015-11-30 | 2018-04-10 | 中国医科大学 | 二苯并氮杂卓二酮类抗肿瘤化合物及其制备方法 |
| WO2018023017A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
| SG11201911776PA (en) | 2017-06-08 | 2020-01-30 | Forendo Pharma Ltd | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases |
| CA3122049C (en) | 2018-12-05 | 2023-10-17 | Forendo Pharma Ltd | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
| CN112321515A (zh) * | 2020-10-21 | 2021-02-05 | 上海馨远医药科技有限公司 | 一种手性1-叔丁基-3-甲基-6-甲基哌嗪-1,3-二甲酸酯的制备方法 |
| CN112321538A (zh) * | 2020-10-28 | 2021-02-05 | 都创(上海)医药开发有限公司 | 一种合成单胺保护的哌嗪-（r/s）2-甲酸酯的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3590389T1 (de) | 1984-08-02 | 1986-08-28 | Schering Corp., Kenilworth, N.J. | Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer |
| PH30747A (en) | 1989-03-10 | 1997-10-17 | Endorech Inc | Combination therapy for the treatment of estrogen sensitive disease. |
| DK0595796T3 (da) | 1989-07-07 | 2003-05-05 | Endorech Inc | Fremgangsmåde til behandling af androgen-relaterede sygdomme |
| CA2062973C (en) | 1989-07-07 | 2003-09-23 | Fernand Labrie | Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| CZ285893B6 (cs) | 1993-05-17 | 1999-11-17 | Endorecherche Inc. | Antiandrogenní sloučenina, její prekursor a farmaceutický prostředek ji obsahující |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| MXPA00008868A (es) | 1998-03-11 | 2003-04-25 | Endorech Inc | Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso. |
| WO2000017163A1 (en) * | 1998-09-22 | 2000-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivatives |
| SK7582001A3 (en) * | 1998-12-18 | 2002-03-05 | Schering Corp | Compound, method of therapy and pharmaceutical composition comprising the same, and its use for farnesyl protein transferase inhibition |
| US6362188B1 (en) * | 1998-12-18 | 2002-03-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
| MY141661A (en) * | 2001-09-06 | 2010-05-31 | Schering Corp | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| ES2347643T3 (es) * | 2001-10-17 | 2010-11-03 | Schering Corporation | Piperin- y piperazinacetamidas como inhibidores de 17beta hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgenos. |
| ES2345146T3 (es) | 2002-11-18 | 2010-09-16 | Schering Corporation | Inhibidores de 17beta-hidroxiesteroides deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos. |
| AU2003293555A1 (en) * | 2002-12-17 | 2004-07-29 | Schering Corporation | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
-
2003
- 2003-12-15 AU AU2003293555A patent/AU2003293555A1/en not_active Abandoned
- 2003-12-15 DE DE60323765T patent/DE60323765D1/de not_active Expired - Lifetime
- 2003-12-15 WO PCT/US2003/039863 patent/WO2004060488A1/en not_active Ceased
- 2003-12-15 ES ES03790505T patent/ES2312845T3/es not_active Expired - Lifetime
- 2003-12-15 EP EP03790505A patent/EP1572299B1/de not_active Expired - Lifetime
- 2003-12-15 JP JP2004565490A patent/JP4585320B2/ja not_active Expired - Fee Related
- 2003-12-15 CA CA002509758A patent/CA2509758A1/en not_active Abandoned
- 2003-12-15 CN CNA2003801094364A patent/CN1744930A/zh active Pending
- 2003-12-15 US US10/735,983 patent/US7053091B2/en not_active Expired - Fee Related
- 2003-12-15 MX MXPA05006485A patent/MXPA05006485A/es active IP Right Grant
- 2003-12-15 AT AT03790505T patent/ATE409065T1/de not_active IP Right Cessation
-
2006
- 2006-02-23 US US11/360,711 patent/US7271175B2/en not_active Expired - Fee Related
-
2007
- 2007-08-09 US US11/836,530 patent/US7485645B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2312845T3 (es) | 2009-03-01 |
| CA2509758A1 (en) | 2004-07-22 |
| US7271175B2 (en) | 2007-09-18 |
| MXPA05006485A (es) | 2005-08-26 |
| CN1744930A (zh) | 2006-03-08 |
| JP2006514054A (ja) | 2006-04-27 |
| AU2003293555A1 (en) | 2004-07-29 |
| US7053091B2 (en) | 2006-05-30 |
| HK1074592A1 (en) | 2005-11-18 |
| EP1572299A1 (de) | 2005-09-14 |
| EP1572299B1 (de) | 2008-09-24 |
| US20040138226A1 (en) | 2004-07-15 |
| DE60323765D1 (de) | 2008-11-06 |
| US7485645B2 (en) | 2009-02-03 |
| JP4585320B2 (ja) | 2010-11-24 |
| WO2004060488A1 (en) | 2004-07-22 |
| US20080004248A1 (en) | 2008-01-03 |
| US20060142338A1 (en) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60323765D1 (de) | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
| PT1347971E (pt) | Inibidores tiazolilicos de tirosina-cinases da familia tec | |
| EA200501805A1 (ru) | Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы | |
| WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
| MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
| SE0102315D0 (sv) | Compounds | |
| EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
| MY134480A (en) | 4-pyrrolidino-phenyl-benzyl ether derivatives | |
| SG10201809390QA (en) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| TW200514772A (en) | Novel tetrahydropyridine derivatives | |
| SE9803710L (sv) | Användning av vissa substanser för behandling av nervrotsskador | |
| AR020345A1 (es) | Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones. | |
| NO20071078L (no) | Antivirale forbindelser | |
| NO20070866L (no) | Antivirale forbindelser. | |
| WO2005041924A3 (en) | Administration of levodopa and carbidopa | |
| MY130792A (en) | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | |
| MXPA04002009A (es) | Composicion farmaceutica que comprende gabapentina o un analogo de la misma y alfa-aminoamida y su uso como analgesico. | |
| TW200517107A (en) | Novel formulation | |
| DE602004017871D1 (de) | Zubereitungen zur behandlung von arthritischen erscheinungen | |
| NO20055612L (no) | Anti-inflammatoriske fosfonatforbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |